Press Releases NewsPress Releases In the Code Blog In the News Media Kit 2025 April 28, 2025 Encoded Therapeutics to Present New Data for CNS Gene Therapy Programs at the ASGCT 28th Annual Meeting February 13, 2025 Encoded Therapeutics Reports Clinical Progress of ETX101 Gene Therapy for Dravet Syndrome, Recaps 2024 Corporate Achievements and Provides 2025 Outlook 2024 November 07, 2024 Encoded Demonstrates Therapeutic Potential of a Vectorized miRNA-based Approach for Angelman Syndrome at the FAST Annual Global Science Summit May 07, 2024 Encoded Therapeutics Presents Preclinical Data Across its Gene Therapy Portfolio at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) April 23, 2024 Encoded Therapeutics Provides Pipeline Updates From Its Vector Engineering Platform Ahead of Four Preclinical Presentations at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) February 26, 2024 Encoded Therapeutics Announces UK CTA Approval for Dravet Syndrome Gene Therapy Candidate ETX101 February 06, 2024 Encoded Therapeutics Announces US IND Clearance and Australian CTA Approval for Dravet Syndrome Gene Therapy Candidate ETX101 2023 May 19, 2023 Encoded Therapeutics Addresses Common Source of Gene Therapy Toxicity While Achieving Precise Brain Expression in Non-Human Primates, Presented at the American Society of Gene and Cell Therapy 26th Annual Meeting 2022 May 18, 2022 Encoded Therapeutics Presents Nonclinical Data Showing Genomic Medicine Platform Yields Selective Expression to Optimize Gene Therapy Performance at the American Society of Gene and Cell Therapy 25th Annual Meeting May 02, 2022 Encoded Therapeutics to Present Nonclinical Data Showing Targeted Brain Expression While De-Targeting the Liver With Genomic Medicine Platform at the American Society of Gene and Cell Therapy 25th Annual Meeting 2021 December 03, 2021 Encoded Therapeutics Presents Data Showing That Children With Dravet Syndrome Experience Early, Substantial Neurodevelopment Deficits and Seizure Burden, at the American Epilepsy Society 2021 Annual Meeting November 23, 2021 Encoded Therapeutics to Present Initial ENVISION Natural History Study Data of Children With SCN1A+ Dravet Syndrome at the American Epilepsy Society (AES) 2021 Annual Meeting 2020 July 22, 2020 Encoded Therapeutics Announces $135 Million Series D Financing to Support First Clinical Trials in SCN1A+ Dravet Syndrome and Advance Preclinical Pipeline of Gene Therapies for Debilitating Neurological Disorders February 11, 2020 Encoded Therapeutics Expands Gene Therapy Leadership with Key Appointment and Promotion 2019 December 18, 2019 Encoded Therapeutics Strengthens Senior Leadership Team with Key Appointments in Regulatory and Human Resources Functions September 17, 2019 Encoded Therapeutics Expands Leadership Team with Key Appointments, Adding Expertise in Manufacturing and Corporate Development June 26, 2019 Encoded Therapeutics, Inc. Announces $104 Million Series C Financing to Advance Lead Gene Therapy Program in Dravet Syndrome and Unveils its Precision Gene Therapy Platform
